December 11th, 2017

ObsEva Files half Year 2023 Financial Statements

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

ObsEva Files half Year 2023 Financial Statements

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Geneva, Switzerland – September 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today published its Half Year 2023 Financial Statements. The Half Year 2023 Financial Statements may be found on the financial section of the Company’s website, here or directly via the link here.

About ObsEva

ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program focused on improving in vitro fertilization success rates. ObsEva is listed on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

For further information, please contact:

For general information:

contact@obseva.ch

For investors information:

IR@obseva.ch

###




Attachment


Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.15
-3.52 (-1.41%)
AAPL  338.40
-2.67 (-0.78%)
AMD  607.87
-22.76 (-3.61%)
BAC  55.47
-1.23 (-2.17%)
GOOG  339.16
-1.92 (-0.56%)
META  715.62
-36.04 (-4.79%)
MSFT  509.22
-6.95 (-1.35%)
NVDA  228.86
+3.79 (1.68%)
ORCL  132.60
-4.50 (-3.28%)
TSLA  357.45
-14.66 (-3.94%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.